Amarin Corporation plc
Investor Relations Department
7 Curzon St.
London AL W1J 5HG
United Kingdom

Visit IR website
Sign-up for email alerts

NASDAQ: AMRN [1]	
Last Trade:	1.05
Trade Time:	4:00 PM ET 17 Oct 2014
Change:	0.00 (0.000%)
Day Range	1.04 - 1.08
52-Week Range	0.94 - 2.75
Volume	876,700
Market Cap. ($M)	183.328
Shares Out (M)	174.598

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Amarin Corporation plc is a late-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. Amarin has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the use of its lead product candidate, AMR101, in the treatment of patients with very high triglyceride levels (the population studied in Amarin's MARINE trial), and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 26, 2012 for the targeted completion of its review. Amarin plans to separately seek approval for use of AMR101 in the treatment of patients with high triglyceride levels who are also on statin therapy for elevated LDL-C levels, the population studied in the ANCHOR trial, if the FDA approves the MARINE indication and after the REDUCE-IT cardiovascular outcomes trial is substantially underway. Each of the MARINE, ANCHOR and REDUCE-IT studies is the subject of a Special Protocol Assessment (SPA) agreement with the FDA. Amarin also has next-generation lipid candidates under evaluation in preclinical development. Amarin's cardiovascular programs capitalize on Amarin's expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in

Stock Performance



Press Releases [View all]

16 Sep 2014
Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study

12 Sep 2014
Amarin Provides Update on ANCHOR Trial SPA Agreement Rescission Appeal

3 Sep 2014
Amarin to Present at the Rodman & Renshaw 2014 Global Investment Conference

7 Aug 2014
Amarin Reports Second Quarter 2014 Financial Results and Provides Update on Operations

5 Aug 2014
Amarin to Report Second Quarter 2014 Results and Host Conference Call on August 7, 2014

Events [View all]

There are no events to display at this time. Please check back later.

Financials [View all]

Second Quarter Financial Results

27 Feb 2014
Annual Report (10-K)

30 Apr 2014
Definitive Proxy Statement

7 Aug 2014
Quarterly Report (10-Q)

9 May 2014
Quarterly Report (10-Q)

7 Nov 2013
Quarterly Report (10-Q)

Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

… (more)